WHAT'S NEW


Tips & Tricks

Handy Tips & Tricks

To get the most out of your subscription, download this PDF document as a quick reminder of some of the helpful and relevant information available at your fingertips.

For example, did you know you could quickly find a document on which tablets or capsules should not be crushed? Or, that one simple search can yield a document on the comparative review, comparative dosage table, and drug consult on opioid withdrawal? Find all this and more! Click here.

Six Easy Steps to the Highest Quality Evidence Available

Need on-the-go access to the highest quality evidence available? Download the Micromedex® Drug Information mobile app for FREE on your Apple iPhone in six easy steps! Click here to visit iMedicalApps.com to view step-by-step instructions!

The Drug Information mobile app delivers actionable recommendations and takes you beyond the package insert to find off-label indications, dosing recommendations, therapeutic class, administration instructions, monitoring parameters, toxicology information, clinical teaching points, and much more!

And, as a Micromedex subscriber, access the Micromedex Drug Interactions and IV Compatibility mobile apps for FREE with your facility’s passwords. Click here for a complete list of available Micromedex mobile applications.



What's New

Selected Product Updates/Enhancements

Enhancements to Improve Patient Safety

Drug dosing and parenteral nutrition support can be particularly complex in neonatal and pediatric populations, leaving some of your most vulnerable patients at risk for preventable adverse drug events and medication errors.

Micromedex Expanded NeoFax and Pediatric Drug and TPN Management offer tools to effectively manage drug and nutritional therapy. And now, with the following enhancements:

  • Reduce errors and ensure patient safety by implementing drug and parenteral nutrition order verification within your workflow. Now available, during pharmacy verification, all orders can be verified, or modified accordingly.
  • Enter your orders one time! Reduce errors and save time by sending your orders directly to the compounder using standard HL7 outbound messaging for parenteral orders and pharmacy compounding.
  • Effectively manage ingredient shortages with the ability to modify parenteral nutrition product tables including amino acids, trace metals, and vitamins.

Click here to watch short videos on how easy it is to use Micromedex Expanded NeoFax and Pediatrics Drug and TPN Management.

Available Now! A New Web Address for Your Micromedex® Products

Our new URL/Internet domain address for Micromedex 2.0, CareNotes, Formulary, RED BOOK, NeoFax and Pediatric products is now http://www.micromedexsolutions.com.

If you access the old address, www.thomsonhc.com, you will be presented with a notification page advising you that the domain name has changed. You will then be automatically redirected to the new domain after 10 seconds. This redirect will remain in place until June 2013. You will not be able to access Micromedex products using www.thomsonhc.com after June 2013.

Don't forget to update your bookmarks today!

Introducing New Training Videos for Micromedex Solutions

Take a short break from your daily routine - and check out our new training videos - designed with you in mind!

Check out these quick, concise videos - perfect for the busy healthcare professional!

  • Micromedex 2.0 Basic Training for Nurses and Pharmacists. Learn tips and tricks for finding answers to your drug, disease and toxicology questions - fast!
  • Micromedex CareNotes Overview for (End User) Point-of-Care Clinicians. Discover patient education opportunities to empower your patients!

Register today!

Substance Names Clarified for Ado-trastuzumab emtansine and ziv-aflibercept

Truven Health Micromedex clarified substance names for ado-trastuzumab emtansine (Kadcyla(TM)) and ziv-aflibercept (Zaltrap(R)) to reflect the recent alert from the Institute for Safe Medication Practices (ISMP). This will prevent confusion with the existing drugs trastuzumab and aflibercept. Truven Health continues to be dedicated to the adherence of the best practices in medicine. Compliance to safety standards is a top priority, and has been for more than 30 years across our organization.

Selected Updates

Selected New Drug Approvals

  • Aripiprazole extended- release IM injection (Abilify Maintena®): New formulation for once monthly administration for the treatment of schizophrenia.
  • Ospemifene (Osphena®): For the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
  • Pomalidomide (Pomalyst®): For the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
  • Ado-trastuzumab emtansine (Kadcyla®): For the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.
  • Clozapine oral suspension (Versacloz®): New formulation for treatment resistant schizophrenia and reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder.
  • Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine): For the treatment of patients showing signs of botulism following documented or suspected exposure to botulinum neurotoxin. The product is derived from horse plasma and contains a mixture of antibody fragments that neutralize all of the seven botulinum nerve toxin serotypes known to cause botulism.

New FDA-Approved Indications

  • Stivarga® (regorafenib): FDA-approval now includes the treatment of patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease.

Drug Safety

  • Peginesatide (Omontys®): All lots of OMONTYS® (peginesatide) Injection were voluntarily recalled to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which may be life-threatening or fatal.
  • Codeine: An updated safety review of codeine use in children led to a new warning and contraindication on use after tonsillectomy and/or adenoidectomy.
  • Exemestane (Aromasin®) – monitoring content: Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment is now recommended, due to the high prevalence of vitamin D deficiency in women with early breast cancer (EBC). Women with vitamin D deficiency should receive supplementation with vitamin D.

Selected Drug Updates

New Off-Label Indications

  • Bevacizumab: Advanced ovarian cancer; first line in combination with carboplatin and paclitaxel (Class IIb, recommended in some)
  • Pemetrexed: Ovarian cancer; recurrent (Class IIb, recommended in some)
  • Amiloride: Edema associated with thiazolidinedione use (Class IIb, recommended in some)
  • Apixaban: Prophylaxis of recurrent venous thromboembolism (Class IIa, recommended in most)
  • Tolvaptan for autosomal dominant polycystic kidney disease (Class IIb, recommended in some)

Selected Content Updates

Updated Drug Consult for Otitis Media – Diagnosis and Management
This Drug Consult has been updated with the American Academy of Pediatrics (AAP) 2013 Clinical Practice Guideline on the Diagnosis and Management of Acute Otitis Media, which was last published in 2004.

Updated Drug Consult for Guidelines – Pharmacologic Management of Diabetes Mellitus
This Drug Consult has been updated with the American Diabetes Association (ADA) 2013 Standards of Care for Diabetes Mellitus, and the AAP 2013 Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in Children and Adolescent guideline.

Updated Content for the Comparative Efficacy of apixaban and aspirin
New information reports results of a subgroup analysis of the AVERROES trial, which compared apixaban and aspirin for the reduction of stroke risk and systemic embolism in patients with nonvalvular atrial fibrillation. In patients with stage III chronic kidney disease, apixaban demonstrated a significant reduction in the composite endpoint of stroke and thrombotic events compared with aspirin, without a significant increase in the risk of major bleeding.